Your browser version may not work well with NCBI's Web applications. More information here...
1: Bioorg Med Chem Lett. 2007 Aug 15;17(16):4664-9. Epub 2007 Jun 7.Click here to read Links

The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.

Research and Development, Boehringer-Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, CT 06877, USA. jwu@rdg.boehringer-ingelheim.com

The discovery of a series of potent, carboline-based MK2 inhibitors is described. These compounds inhibit MK2 with IC50s as low as 10 nM, as measured in a DELFIA assay. An X-ray crystal structure reveals that they bind in a region near the p-loop and the hinge region of MK2a.

PMID: 17576063 [PubMed - indexed for MEDLINE]

Structures reported by this article